Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock With Promising Growth Prospects
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
GSK Target Cut to GBP13.50 From GBP17.00 by Deutsche Bank
GSK Cut to Hold From Buy by Deutsche Bank
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK Analyst Ratings
GSK Target Cut to 1,525p From 2,000p by Jefferies
Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $39.5
GlaxoSmithKline (GSK) Was Downgraded to a Hold Rating at Jefferies
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
GSK Cut to Neutral From Buy by Guggenheim
GSK Analyst Ratings
Guggenheim Downgrades GlaxoSmithKline(GSK.US) to Hold Rating
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)
GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
GlaxoSmithKline (GSK) Gets a Hold From Kepler Capital